Patient-Friendly Explanation

Pramlintide, known by the brand name Symlin, is an injectable medication originally developed for diabetes management. It works by mimicking amylin — a hormone your pancreas naturally produces alongside insulin — to slow down how quickly food leaves your stomach, making you feel fuller for longer and reducing post-meal blood sugar spikes. Because of its appetite-suppressing effect, it has also been studied as a weight-loss aid.

Clinical Definition

Pramlintide is a synthetic analogue of the neuroendocrine hormone amylin, co-secreted with insulin from pancreatic beta cells. It acts as an amylin receptor agonist, slowing gastric emptying, suppressing postprandial glucagon secretion, and modulating central appetite pathways via the area postrema. It is FDA-approved as an adjunct to mealtime insulin for type 1 and type 2 diabetes. In clinical trials, pramlintide produced modest but significant weight loss (1.5–2.5 kg over 6–12 months) independent of glycaemic improvement, making it an attractive option for overweight patients with insulin-requiring diabetes.

Why It Matters

For patients with diabetes who struggle with both blood sugar control and weight, pramlintide offers a dual-benefit treatment option. At NuLifeCare, our doctors assess whether amylin-based therapies could complement your diabetes and weight management plan, alongside nutrition and lifestyle interventions.